Literature DB >> 30856298

Subependymoma involving multiple spinal cord levels: A clinicopathological case series with chromosomal microarray analysis.

Anthony L Mikula1, Michael A Paolini2, William R Sukov2, Michelle J Clarke1, Aditya Raghunathan2.   

Abstract

Subependymomas of the spinal cord are rare, do not often involve multiple levels, and very rarely recur. Here, we present a series of spinal cord subependymomas with a detailed description of the clinical, radiological and pathological features, and characterization by chromosomal microarray analysis. Briefly, the four patients included two men and two women, between the ages of 22 and 48 years. The most common presenting symptoms were neck and arm pain with upper extremity weakness. By imaging, the tumors were found to involve multiple spinal levels, including cervical/ cervico-thoracic (three patients) and thoracic (one patient), were all eccentric, and had minimal to no post-contrast enhancement. Two patients underwent gross total resection, one had a sub-total resection, and one underwent biopsy alone with a decompressive laminectomy. Follow up ranged from 6 months to 22 years. One patient (case 4) had recurrence 15 years following gross total resection and chromosomal microarray analysis revealed deletions on the long arm of chromosome 6. Our limited series suggests that spinal cord subependymomas can rarely recur, even following gross total resection, suggesting a possible role for long-term surveillance for these rare tumors.
© 2019 Japanese Society of Neuropathology.

Entities:  

Keywords:  chromosomal microarray; intramedullary tumor; long term recurrence; spinal cord; subependymoma

Mesh:

Year:  2019        PMID: 30856298     DOI: 10.1111/neup.12543

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  1 in total

1.  Spinal cord subependymoma mimicking syringomyelia in a child: a case report.

Authors:  Masahiro Oishi; Hironori Fujisawa; Katsuhiro Tsuchiya; Yoshio Nakashima
Journal:  Childs Nerv Syst       Date:  2020-10-27       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.